- Home
- RITR vs CGEN Comparison
RITR vs CGEN Comparison
Compare RITR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- CGEN
- Stock Information
- Founded
- RITR 2015
- CGEN 1993
- Country
- RITR Hong Kong
- CGEN Israel
- Employees
- RITR N/A
- CGEN N/A
- Industry
- RITR
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RITR
- CGEN Health Care
- Exchange
- RITR NYSE
- CGEN Nasdaq
- Market Cap
- RITR 166.1M
- CGEN 149.6M
- IPO Year
- RITR 2024
- CGEN 2000
- Fundamental
- Price
- RITR $2.68
- CGEN $1.46
- Analyst Decision
- RITR
- CGEN Strong Buy
- Analyst Count
- RITR 0
- CGEN 1
- Target Price
- RITR N/A
- CGEN $4.00
- AVG Volume (30 Days)
- RITR 35.7K
- CGEN 286.0K
- Earning Date
- RITR 02-15-2025
- CGEN 03-04-2025
- Dividend Yield
- RITR N/A
- CGEN N/A
- EPS Growth
- RITR N/A
- CGEN N/A
- EPS
- RITR 0.09
- CGEN N/A
- Revenue
- RITR $47,948,887.00
- CGEN $27,864,000.00
- Revenue This Year
- RITR N/A
- CGEN $22.94
- Revenue Next Year
- RITR N/A
- CGEN $15.88
- P/E Ratio
- RITR $30.65
- CGEN N/A
- Revenue Growth
- RITR 278.44
- CGEN N/A
- 52 Week Low
- RITR $2.24
- CGEN $1.35
- 52 Week High
- RITR $8.75
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- CGEN 32.02
- Support Level
- RITR N/A
- CGEN $1.50
- Resistance Level
- RITR N/A
- CGEN $1.65
- Average True Range (ATR)
- RITR 0.00
- CGEN 0.07
- MACD
- RITR 0.00
- CGEN 0.00
- Stochastic Oscillator
- RITR 0.00
- CGEN 12.50
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.